Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. - Concepedia

Concepedia

Publication | Closed Access

Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis.

44

Citations

0

References

2000

Year

Larry W. Moreland, Dorothy McCabe, J R Caldwell, Marshall Sack, M H Weisman, Guylaine Henry, James E. Seely, Steven W. Martin, C L Yee, A.M. Bendele,

Abstract

TNFbp dimer administered to patients with long standing RA resulted in significant antibody production to the study drug. This effect reduced the half-life and clearance of the TNFbp. This TNFbp will not be a viable option for treating patients with RA secondary to immunogenicity.